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INTRODUCTION 13 
At least one in four people in the UK will experience a mental health problem and up to two 14 
percent of the population will be diagnosed with a serious mental illness (SMI) during their 15 
lifetime (1). For the purposes of this research SMI is considered to include diagnoses that are 16 
treated with antipsychotics, typically schizophrenia and bipolar affective disorder (2). The adverse 17 
effects of antipsychotics can decrease adherence rates (3).  18 
Adherence, the currently accepted term used for medication-taking behaviour, is defined ‘as the 19 
extent to which the patient's action matches the agreed recommendations’ (4). Adherence presumes 20 
agreement about the proposed medication, between the prescriber and the person taking the 21 
medicine, emphasising the importance of shared decision-making (SDM; 4).  A third to a half of all 22 
medications for long-term conditions are not taken as recommended, and treatment adherence is 23 
one of the biggest challenges in mental health (4,5). Adherence in SMI is very poor; estimated non-24 
adherence rates for people diagnosed with schizophrenia range from 40 to 75% (6,7). Studies have 25 
found that 75% of people with chronic schizophrenia discontinue their medication within 18 26 
months (8) and non-adherence rates in bipolar disorder ranges between 20 to 60% with a mean of 27 
41% (9,10). Antipsychotic prescribing lends itself to SDM, because the adverse event profile is the 28 
main factor in the choice of antipsychotics (11). 29 
SDM is defined by the NHS as ‘the conversation that happens between a patient and their 30 
healthcare professional to reach a healthcare choice together’, where both parties consider what is 31 
important to the other when selecting treatment. There are ethical, clinical and economic 32 
arguments for SDM (12); it represents a method of healthcare communication that promotes 33 
patient-centred care and sharing expertise between clinicians and service users (13,14). The most 34 
accepted model is that of Charles and colleagues, which emphasises patient autonomy, informed 35 
consent and empowerment (15). SDM is founded on partnership and opposed to a paternalistic 36 
model of healthcare (16). A recent Department of Health White Paper stated that ‘care should be 37 
personalised to reflect peoples’ needs, not those of the professional or the system’ and patients 38 
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should be involved in treatment decisions (17). People diagnosed with SMI can be fully engaged 39 
with making decisions and seek a more collaborative approach, thus treatment decisions should be 40 
made by the service user and the healthcare professional working together and considering both the 41 
likely benefits and possible adverse effects of the medication (11,18).  42 
SDM has been linked to improved quality of care and service user satisfaction (19,20). However, 43 
the evidence base supporting the use of SDM for chronic conditions, notably mental health (21) 44 
and the use of SDM for decisions made on multiple occasions over the longer-term is limited. 45 
Hamann (2006) found that SDM increased knowledge and perceived involvement in treatment in 46 
inpatients with schizophrenia (22). However, SDM failed to show long-term benefits in the same 47 
study (23). A Cochrane review found that no conclusions could be drawn regarding the 48 
effectiveness of SDM interventions for people with mental health problems and highlighted the 49 
urgent need for more research (13). A more recent study found that although a pharmacist 50 
intervention based on SDM significantly improved adherence, treatment satisfaction and beliefs 51 
about medication in people with depression, it had no significant effect on depressive symptoms 52 
(24).   53 
Both service users and clinicians appear to support SDM (25). However, only 32% of service users 54 
report that their views about treatment were considered ‘to some extent’ and less than half (43%) 55 
were informed about adverse effects, suggesting clinicians are not engaging in SDM (26). The lack 56 
of a multi-disciplinary approach and the perceived difficulty of implementing SDM with service 57 
users who may lack insight are barriers to SDM across mental healthcare (21,27). In addition, there 58 
are structural obstacles to collaborative care in psychiatry which include timely access to relevant, 59 
reliable clinical information, and therefore research is vital to understand the practicalities of SDM 60 
in practice (21,28,29).  61 
Whilst experiences of and attitudes of consultant psychiatrists towards shared decision making in 62 
antipsychotic prescribing have been studied, qualitative data on the views of other key groups of 63 
healthcare professionals involved in medication management across mental health services, 64 
including pharmacists, is lacking (21). This study aimed to understand the views and opinions of 65 
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mental health pharmacists in the UK who are increasingly developing clinical roles. These clinical 66 
roles include; advising prescribers and clinicians on the most appropriate medication after 67 
interviewing patients; patient education and advocacy; attending and directly inputting into multi-68 
disciplinary meetings.  These roles are generally independent from the prescribing process 69 
although a limited number of pharmacists may have a caseload with a prescribing role.  70 
AIM 71 
To elucidate the experiences and opinions of mental health pharmacists about implementing SDM 72 
in the process of antipsychotic choice and prescribing in SMI.  73 
ETHICS APPROVAL 74 
The project received approval from the Aston University Ethics Committee. 75 
METHODS 76 
Design 77 
An exploratory qualitative study design that followed COREQ (Consolidated Criteria for 78 
Reporting Qualitative studies) guidelines (30) was employed. 79 
Participant Recruitment and Consent 80 
Mental health pharmacists with a minimum of 12 months experience in mental health pharmacy 81 
practice were recruited, on the basis that they are more likely to have an understanding of SDM 82 
and be undertaking advanced clinical roles.  Participants were recruited from the Midlands region 83 
of the UK. Initially convenience sampling was used; known contacts meeting the inclusion criteria 84 
were identified (31). Further participants were recruited through active snowballing (32). Potential 85 
participants were emailed with the project aims and participation requirements. Written informed 86 
consent was obtained prior to participation. 87 
Inclusion Criteria 88 
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Mental health pharmacists with a minimum of 12 months experience in mental health pharmacy 89 
practice. 90 
Interview Structure and Collection 91 
A semi-structured interview was used to allow the interviews to be participant-led and participants 92 
to express their views openly (33,34,35). An initial interview topic guide, based on the literature on 93 
research into SDM in mental health, was constructed to focus the interviews (36). This guide was 94 
reviewed and amended by the academic supervisor (IM) and two practising mental health 95 
pharmacists (NH, DS; see appendix 1 for schedule). The schedule was adapted following each 96 
interview, using an iterative approach (37,38). Participants were given a chance to provide 97 
feedback and suggest questions to be included in the topic guide. Eleven face-to-face and two 98 
phone interviews were conducted; each lasted between twenty and thirty five minutes. These 13 99 
interviews were deemed sufficient to provide the necessary identification of themes. The 100 
transcripts were reviewed after each interview and data saturation was perceived to have been met 101 
as no new themes were identified in the last set of interviews (39). Interviews were audio recorded 102 
and a verbatim account produced from these recordings (40). The recordings were checked against 103 
the transcripts several times (41). 104 
 105 
Data Analysis 106 
Thematic analysis, based on the identification of themes, was conducted by MY (34). The 107 
transcripts were independently reviewed by IM; any disagreements on the coding scheme were 108 
resolved by discussion between IM and MY. 109 
The constant comparison method informed by grounded theory was used whereby the data analysis 110 
takes place alongside data collection (42,43). Each interview was reviewed before the next 111 
commenced to identify emerging patterns in the data and assist structuring of further interviews 112 
(33). Coding took place in three stages (35,44), as follows:  113 
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• Open coding was used to identify themes; coding and categories were refined.  114 
• Axial coding was then used. Extracts were photocopied from the original data and 115 
arranged with the codes together in files.  116 
• Selective coding was used; data was analysed and re-organised. Themes were arranged 117 
according to their relation to the research question. 118 
Reflexivity 119 
Qualitative research as a process necessitates and acknowledges the key role of reflexivity, and the 120 
important role played by any researcher’s background, perceptions and interests in the topic  121 
(72,73).  Within this study, the interviews were conducted by a female pharmacy undergraduate 122 
student of Indian sub-continent descent. In preparation for the study, the student received training 123 
in research methods including qualitative research, supervisory guidance during the development 124 
of the interview schedule and support from the research team in relation to the interpretation and 125 
analytic process.   126 
 127 
RESULTS 128 
Fifteen participants were recruited but two interviews didn’t take place due to time constraints. Of 129 
the 13 participants interviewed the majority were aged between 30 and 40 years old (six of the 11 130 
participants who reported this information). Ten participants were female and three were male. 131 
Four main themes were identified: attitudes to SDM; barriers to implementation; benefits of SDM; 132 
and the role of mental health pharmacists. 133 
 134 
1. Attitudes to Shared Decision Making 135 
Pharmacist Attitudes 136 
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Almost all the pharmacists felt SDM was a positive concept and supported its use in antipsychotic 137 
prescribing. 138 
‘I totally support the idea…they’re powerful drugs therefore….patients should have the 139 
opportunity to articulate what factors are most important to them and this should be taken into 140 
consideration when choosing treatment’. (In01) 141 
The complexity of antipsychotic use was recognised, with reference in particular to side effects and 142 
the impact on adherence rates.  For these reasons, patient choice was highlighted as being 143 
particularly important: 144 
‘The choice should be dependent on what the patient will tolerate in regards to side effects’. (In13) 145 
The pharmacists believed that it was important to involve service users in the discussion, even if 146 
agreement could not be reached. 147 
‘We get that quite a lot. We have involved them in the treatment plan but they might not agree still 148 
with the decision that we have tried to involve them with’. (In06) 149 
However, some pharmacists viewed SDM as a tool to achieve adherence, to persuade the patient to 150 
take the medication, rather than an agreement negotiated between two equal parties. 151 
‘A few cases it has helped but we still need to persist in getting them to take their medication so it’s 152 
still an issue. Once they realise that medication is important they feel better then 153 
hopefully…sometimes when we have given them a lot of choice the patient seems to change their 154 
mind a lot’. (In06) 155 
The views of Pharmacists on the Attitudes of Prescribers 156 
Pharmacists believed that attitudes towards SDM amongst prescribers were variable. 157 
‘There’s a very broad church amongst (prescribers)...some are excellent and some have the view 158 
the patients should do as they’re told’. (In04) 159 
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The majority, however, felt that there had been a positive cultural shift, with attitudes moving 160 
towards greater service user involvement. 161 
‘Attitudes have definitely changed in my 16 years in mental health, early on it was very much…I’m 162 
the doctor and this is what’s right. I think health as a whole has shifted…engaging with the patient 163 
a lot more. At one time…it was…if you tell patients about side effects they won’t take the 164 
medication’. (In03) 165 
However, some pharmacists felt that SDM was not practised as widely as it should be due to the 166 
perceived difficulties in relation to patient engagement: 167 
‘I’m not saying…they don’t want to involve patients but I think it’s because of the difficulty of 168 
engaging patients’. (In11) 169 
The views of Pharmacists on the Attitudes of Service Users  170 
The pharmacists also believed that the attitudes of service users towards SDM were variable; some 171 
service users were seen to want involvement in the decision-making process whereas others 172 
preferred the clinicians to make the decisions. 173 
‘Some patients want to be told what to do; other patients want…to make the decision themselves’. 174 
(In04) 175 
There was, however, a general consensus amongst the pharmacists that service users, particularly 176 
younger service users, were increasingly wanting to be involved in the decision-making process 177 
and have more choice, partly due to changes in society.  178 
‘They crave that involvement and…empowerment…in a largely consumerist society people want 179 
and expect choice and…more autonomy’. (In01) 180 
2. Barriers to Implementation of SDM 181 
Capacity and Insight 182 
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A lack of service user insight was seen by the participants as an obstacle to SDM.  183 
‘If they don’t have insight…it doesn’t matter what decision you make or information you give 184 
(them)…(if they believe that) there’s nothing wrong with them they don’t need to take treatment.’ 185 
(In04) 186 
Several pharmacists highlighted the fact that when treatment decisions (initiation, dose change or 187 
switching) are frequently made, that service users are often acutely unwell and so these are times 188 
of difficulty in relation to SDM. Moreover, if they are detained under the mental health act then 189 
treatment decisions may be imposed on the service user as being in their best interests rather than 190 
attempting to overcome the barriers associated with SDM at these points:  191 
‘They might be acutely unwell...they might not be in a position to make a decision they might be 192 
forced to have treatment against their wishes so in that scenario you’re not going to be able to 193 
provide them with SDM’. (In03) 194 
When medication regimes were working well, there was often hesitancy from clinicians to make 195 
changes.  196 
‘Switching a treatment when they have been stabilised a long period of time is actually a very 197 
scary thing to do.’ (In13) 198 
However, the majority of pharmacists felt that SDM could be implemented with most of the 199 
service users, most of the time:  200 
‘If you are flexible in your approach…but nevertheless you can still have some degree of 201 
conversation to enable them to be a part of the SDM process the vast majority of the time.’ (In07) 202 
Time 203 
Time was a key barrier to SDM.  Pharmacists believed that clinicians often did not have the 204 
opportunity to speak to service users or time to fully implement techniques of SDM: 205 
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‘It takes a lot longer than just writing a prescription.’ (In06) 206 
Such time pressures were increasingly problematic with services experiencing high demand:  207 
‘There’s always a demand for beds, it does have an impact on SDM.’ (In05) 208 
‘Not having the time in outpatient clinics.’ (In13) 209 
3. Potential Benefits of SDM 210 
Adherence 211 
Pharmacists felt that if service users were genuinely involved in the prescribing decision, this could 212 
improve adherence. 213 
‘If they’re taking part in the decision they have an interest in the outcome...if you don’t involve 214 
them and you are imposing something, as soon as they go out of the door they won’t actually be 215 
interested in continuing with it.’ (In05) 216 
Mental health was viewed as similar to any other chronic illness management in that giving more 217 
autonomy to service users improved adherence to medication. 218 
‘I think it’s like any other condition…the more autonomy you give the patient…the more likely they 219 
are to comply.’ (In10) 220 
Importantly, the absence of SDM was believed to result in non-adherence and high rates of re-221 
admission to hospitals. 222 
‘It’s not as high as it ought to be otherwise…they wouldn’t have so many patients relapsing, we 223 
have these revolving door patients that keep coming in again and again, people just don’t take 224 
their medication’. (In02) 225 
However, there was recognition that those service users who were engaged and interested in SDM 226 
could be those who were more likely to be adherent regardless of approach. 227 
‘Those patients who can actually engage are more likely I think to actually be concordant’. (In11) 228 
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Service User Satisfaction 229 
Service users were said to respond well to SDM, and appreciate being involved in decisions about 230 
their care, improving the therapeutic alliance. One pharmacist who believed that SDM had a 231 
positive effect on the therapeutic alliance quoted one service user saying: 232 
‘You were one of the few people who saw me as a human being and gave me a choice, when 233 
everyone else was just telling me what to do.’ (In07) 234 
SDM could help service users feel more valued and respected, and work towards removing some 235 
of the stigma that is associated with mental health. 236 
‘It’s huge stigma all around… so if you treat them like every other human being… they’re going to 237 
feel valued and respected definitely …there’s definite improvement, they feel at the centre of their 238 
care…they will respect you for giving them that rather than being domineering and telling them.... 239 
I know better than you.’ (In02) 240 
4. The Role of the Mental Health Pharmacist 241 
Service User Counselling 242 
The pharmacists felt that service users were often more open about medication issues with them 243 
than other health professionals, particularly about sensitive side effects such as sexual dysfunction. 244 
‘I’ve had a patient discuss sexual dysfunction with myself……where they didn’t discuss it on the 245 
ward review because they felt embarrassed to talk about it with the consultant.’ (In13). 246 
Pharmacists felt they were often seen as an independent person compared to the prescriber and 247 
therefore able to have an open conversation with service users about medication. 248 
‘I do think we’re in a very good position to discuss things because we are….seen as independent. 249 
(In10) 250 
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More research into the impact pharmacists can have upon clinical outcomes such as relapse rates 251 
was suggested.  252 
‘I think we could reduce (the) relapse rate. Somebody needs to do a study into pharmacist 253 
input….and the impact it has on non-concordance.’ (In13) 254 
Multi-Disciplinary Team (MDT) Working 255 
The level of input that mental health pharmacists have in SDM was dependent on the leadership of 256 
the MDT, with some clinical teams more collaborative than others, and resourcing within 257 
pharmacy services.  258 
‘Some of the clinical teams I’m in are very collaborative and very collegiate… I’ve also worked in 259 
teams where there’s very little conversation apart from between nurses and doctors, me as the 260 
pharmacist has to almost fight to say something.’ (In07) 261 
Mental health pharmacists clearly felt that they had more to offer and were often underutilised. 262 
‘I think they have a really difficult job, but if they let us help them, a bit more in recognising we 263 
have a resource here, that we can actually use that we have the knowledge.’ (In11) 264 
Pharmacists believed that a more inter-disciplinary approach with a referral system could support 265 
their involvement in SDM.  266 
‘Some way of referring patients to a pharmacist clinic….but there’s no actual referral process’ 267 
(In13) 268 
 269 
DISCUSSION 270 
Pharmacist participants were supportive in principle for SDM, particularly when considering the 271 
use of antipsychotic medication, and believed that practising SDM was a key part of stigma-free 272 
clinical care. Like previous research, the pharmacists felt SDM increased service user satisfaction, 273 
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which in turn improved the therapeutic relationship and was key to achieving long term treatment 274 
success and positive outcomes by improving adherence to medication (19,45-50).  275 
The pharmacists perceived that attitudes of both services users and prescribers to SDM varied. 276 
Some pharmacists felt that a minority of service users were happy with the clinician making 277 
treatment decisions on their behalf. Other research has also identified this group who believe ‘the 278 
doctor knows best’; perhaps because they undervalue their expertise in relation to clinicians and 279 
want to be ‘a good patient’ (47,51). Most service users, however, particularly those in younger age 280 
groups, were said by the pharmacists to increasingly crave involvement, which is in line with 281 
previous research (27,46,52). This change may reflect an increasingly consumerist society, where 282 
choice was expected (53-55). 283 
A strong, trusting relationship, with health care professionals and service users both accepting an 284 
active role, is essential to the success, or otherwise of SDM (47). Yet service users often describe 285 
mixed feelings, that they are both helped and misunderstood by healthcare professionals, and 286 
commonly report experiencing discrimination (56,57). SDM involves the clinician respecting the 287 
right of service users to make treatment decisions, even if they disagree with this decision (58). 288 
However, like other research, we found a mixed picture; the pharmacists perceived that some 289 
prescribers adopted an authoritative approach, dominating consultations and failing to take into 290 
account the views of service users (26,59-62).  291 
The participants perceived a lack of service user insight as the main barrier to SDM. Service users 292 
suffering from acute illness were said to lack capacity precisely when medication was most likely 293 
to be initiated or changed and, therefore, when SDM was important. However, when the illness 294 
being treated was well controlled, and the service user may be more likely to be able to be engaged 295 
in SDM, the pharmacists perceived that clinicians would be reluctant to change medication due to 296 
concerns about the illness becoming less well-controlled.  297 
Generally the pharmacists reported that SDM was not possible with service users treated under the 298 
Mental Health Act without their consent (63). This act is designed to protect the rights, health and 299 
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safety of people with a mental health disorder and the safety of others; it covers the circumstances 300 
in which someone can be detained for treatment (63). Unlike other studies, some pharmacists in 301 
this study did not view capacity in absolute terms (21). They felt more should be done to engage 302 
service users and that SDM should be attempted with all service users to varying degrees 303 
depending on the level of insight and capacity. This echoes other research, which has found that 304 
service users with SMI value the opportunity to collaborate with those providing their care and are 305 
prepared to engage with SDM within the current patient-professional relationship (47). SDM can 306 
also improve treatment knowledge amongst service users with schizophrenia potentially reducing 307 
the risk of medication errors (18,64-66).  308 
However, rather than focus on individual barriers, it may be more relevant to consider structural 309 
barriers to SDM in mental health practice such as a lack of time, poor communication between 310 
clinicians and service users, and limited access to evidence-based information (28,58). SDM can be 311 
seen to be a time consuming activity to undertake (22,27). In this research pharmacists reported the 312 
lack of time of both pharmacists and prescribers to be a barrier, with pharmacists identifying that 313 
other duties were seen to override SDM; other research has found that lack of time is a commonly 314 
reported barrier by both health professionals and service users (27,51,59,60).   315 
The pharmacists felt they were able to play a vital role in SDM partly because their independence 316 
from the prescribing process enabled them to engage in SDM. Previous research has identified the 317 
need for an inter-disciplinary approach involving autonomous clinicians to engage service users in 318 
SDM (67-70). However, many of the pharmacists felt that they did not always get the opportunity 319 
to be involved in the SDM process due to the lack of a structured referral system and multi-320 
disciplinary approach or resources issues within pharmacy departments. 321 
Implications of Study 322 
Services should be structured to support SDM with a more inter-disciplinary approach. This could 323 
include a formal referral system to pharmacists or implementation of pharmacist clinics. Training 324 
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for pharmacists (and potentially other clinicians) should highlight that SDM should be adapted 325 
depending on the state of illness at the time, but not abandoned.  326 
 327 
Further Study  328 
Further qualitative research on SDM, and more specifically the potential role of pharmacy, 329 
involving pharmacists, other clinicians and service users is required. Research is also required on 330 
the impact of SDM on outcomes including adherence to medication (19,48-50,71). Future research 331 
should investigate whether clinicians use SDM differentially depending on various characteristics 332 
including how long they have known the service user for and what the medication is being utilized 333 
for. It could also cover service users’ views on the role of family members as advocates. Previous 334 
research has identified a role for healthcare professional ‘coaches’ not involved in treatment to 335 
actively support service users in engaging in SDM (58). Therefore, future research could 336 
investigate the impact of ‘pharmacy medication management coaches’ on key outcomes.  337 
 338 
 339 
 340 
Limitations  341 
All the participants recruited for the study came from the Midlands region and may not be broadly 342 
representative of attitudes and experiences of mental health pharmacists nationally and 343 
internationally. Moreover, we cannot be sure how long the participants had worked in mental 344 
health for (other than more than one year), whether they have a formal mental health qualification 345 
or their area of practice. We relied on convenience and snowballing sampling and relatively small 346 
sample sizes; however we found data saturation with consistent themes identified and no new 347 
themes identified in the last set of interviews. Additionally, identifying participants via known 348 
contacts may have influenced the interview responses in relation to socially desirable responses. 349 
This research project only sought the views of mental health pharmacists; a future project should 350 
triangulate the data collection methods and also interview other clinicians and more importantly 351 
service users. Pharmacists are increasingly becoming prescribers and therefore a future research 352 
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should also compare and contrast the views and experiences of prescribing and non-prescribing 353 
(who are independent from the prescribing process) pharmacists. 354 
 355 
CONCLUSION 356 
In keeping with previous research in this area, SDM was seen as a positive concept by the mental 357 
health pharmacists interviewed. SDM should take into consideration the service user’s ability to 358 
tolerate adverse effects and their preferences regarding medication. The pharmacists believed that 359 
such an approach could improve service users’ satisfaction with medication management services 360 
and ultimately adherence to medication. The pharmacists perceived that the attitudes of prescribers 361 
and service users, although noted as variable, were considered to be increasingly in favour of 362 
SDM.  363 
   364 
The pharmacists identified that the use of SDM was limited by barriers, particularly the difficulties 365 
perceived by clinicians of engaging people with SMI who lack insight and mental capacity in the 366 
process. Greater effort is seen to be needed to work around these issues and try to engage service 367 
users as much as possible. Structural issues, such as time pressures may also limit the use of SDM.  368 
Pharmacists clearly feel they can play a vital role in SDM but their skills and knowledge in this 369 
area being underutilised, limiting their opportunity to contribute. SDM is clearly seen as one way 370 
to improve outcomes, and more research on how it be effectively implemented in mental health is 371 
required. 372 
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